Interactive Financial Charts Not Available

Neovacs (ALNEV) | Financial Analysis & Statements

Neovacs | Small-cap | Healthcare

€0.78

-8.22%

Neovacs vs Abivax SA Neovacs vs Valneva SE Neovacs vs Ose Neovacs vs Transgene S.A Neovacs vs Adocia S.A Neovacs vs CAC 40 | Market

TL;DR Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Income Metrics

Balance Sheet Metrics

Total Assets 22.1M

Total Liabilities 4.0M

Shareholders Equity 18.1M

Debt to Equity 0.22

Cash Flow Metrics

Revenue & Profitability Trend

Interactive Financial Charts Not Available

This page uses interactive financial charts and dynamic data visualization tools that require JavaScript. For detailed financial analysis:

Available Financial Data:

Income statements (annual and quarterly)
Balance sheets with asset and liability details
Cash flow statements and free cash flow analysis
Key financial ratios and performance metrics
Peer comparison and industry benchmarking

All financial data is displayed in accessible table format below. Use the table headers and structure to analyze trends and compare metrics across different periods.

Neovacs Income Statement From 2020 to 2024

Metric	2024	2023	2022	2021	2020
Revenue i	366.3K	534.3K	2.5K	22.6K	30.1K
Cost of Goods Sold i	323.9K	504.1K	577.4K	484.9K	120.0K
Gross Profit i	42.4K	30.2K	-574.9K	-462.3K	-89.9K
Gross Margin % i	11.6%	5.6%	-23,192.0%	-2,046.1%	-298.1%
Operating Expenses
Research & Development i	-	-	-	-	-
Selling, General & Administrative i	-	-	-	4.1M	1.6M
Other Operating Expenses i	3.0M	3.7M	3.8M	4.3M	1.7M
Total Operating Expenses i	3.0M	3.7M	3.8M	8.4M	3.3M
Operating Income i	-13.7M	-12.3M	-6.8M	-7.9M	-3.6M
Operating Margin % i	-3,731.8%	-2,305.1%	-273,345.0%	-34,922.6%	-12,012.7%
Non-Operating Items
Interest Income i	1.1M	1.5M	1.2M	45.2K	3.3K
Interest Expense i	0	0	0	364	844
Other Non-Operating Income	-	-	-	-	-
Pre-tax Income i	-33.9M	-9.6M	-4.3M	-12.5M	-6.7M
Income Tax i	-1.0M	-876.8K	-797.4K	-641.0K	-541.5K
Effective Tax Rate % i	0.0%	0.0%	0.0%	0.0%	0.0%
Net Income i	-32.9M	-8.7M	-3.5M	-11.8M	-6.1M
Net Margin % i	-8,984.5%	-1,636.5%	-143,142.5%	-52,389.0%	-20,379.1%
Key Metrics
EBITDA i	-25.1M	-3.7M	-2.7M	-9.5M	-5.4M
EPS (Basic) i	€-221.36	€-249,812.86	€-1,182,834.33	€-47,731.06	€-767,832.63
EPS (Diluted) i	€-221.36	€-249,812.86	€-1,182,834.33	€-47,731.06	€-767,832.63
Basic Shares Outstanding i	269590	35	3	248	8
Diluted Shares Outstanding i	269590	35	3	248	8

Income Statement Trend

Neovacs Balance Sheet From 2020 to 2024

Metric	2024	2023	2022	2021	2020
Assets
Current Assets
Cash & Equivalents i	435.4K	887.1K	43.1K	16.2M	10.1M
Short-term Investments i	8	-	6.7M	16.8M	-
Accounts Receivable i	305.8K	572.9K	6.6K	5.3K	75.0K
Inventory i	-	-	-	-	-
Other Current Assets	41.7K	107.2K	30.1K	145	188
Total Current Assets i	2.5M	3.8M	9.1M	34.8M	13.1M
Non-Current Assets
Property, Plant & Equipment i	193.7K	79.5K	119.7K	98.6K	127.6K
Goodwill i	441	876	2.6K	1.3K	0
Intangible Assets i	441	876	2.6K	1.3K	-
Long-term Investments	-	-	-	-	-
Other Non-Current Assets	-	-	-1	1	-1
Total Non-Current Assets i	19.6M	48.7M	46.2M	13.8M	435.1K
Total Assets i	22.1M	52.6M	55.3M	48.6M	13.5M
Liabilities
Current Liabilities
Accounts Payable i	2.3M	2.0M	1.9M	1.3M	1.3M
Short-term Debt i	230.4K	586	4.0K	5.0K	1.5K
Current Portion of Long-term Debt	-	-	-	-	-
Other Current Liabilities	205.1K	32.4K	514.8K	1.4M	111.8K
Total Current Liabilities i	4.0M	3.1M	3.9M	3.6M	2.1M
Non-Current Liabilities
Long-term Debt i	-	650.0K	1.2M	1.0M	310.0K
Deferred Tax Liabilities i	-	-	-	-	-
Other Non-Current Liabilities	-	-	-	1	1
Total Non-Current Liabilities i	6.9K	651.8K	1.2M	1.0M	392.0K
Total Liabilities i	4.0M	3.7M	5.1M	4.7M	2.5M
Equity
Common Stock i	174.5K	351.7K	121.4K	2.0M	675.2K
Retained Earnings i	-60.3M	-94.6M	-89.6M	-93.2M	-94.0M
Treasury Stock i	-	-	-	-	-
Other Equity	-	-	-	-	-
Total Shareholders Equity i	18.1M	48.8M	50.2M	43.9M	11.0M
Key Metrics
Total Debt i	230.4K	650.6K	1.2M	1.0M	311.5K
Working Capital i	-1.5M	772.7K	5.2M	31.2M	11.0M

Balance Sheet Composition

Neovacs Cash Flow Statement From 2020 to 2024

Metric	2024	2023	2022	2021	2020
Operating Activities
Net Income i	-32.9M	-8.7M	-3.5M	-11.8M	-6.1M
Depreciation & Amortization i	-	-	-	-	-
Stock-Based Compensation i	-	-	-	-	-
Working Capital Changes i	0	0	0	0	0
Operating Cash Flow i	-12.5M	-8.7M	-3.5M	-11.8M	-6.1M
Investing Activities
Capital Expenditures i	-79.7K	-203.4K	-152.7K	-348.9K	-206.9K
Acquisitions i	-	-	-	-	-
Investment Purchases i	-493.4K	-13.7M	-34.0M	-18.5M	-15.8K
Investment Sales i	2.0M	2.9M	2.6M	68.4K	0
Investing Cash Flow i	1.5M	-11.1M	-31.6M	-18.8M	-222.7K
Financing Activities
Share Repurchases i	-	-	-	-	-
Dividends Paid i	-	-	-	-	-
Debt Issuance i	1.1M	6.2M	9.0M	46.8M	14.0M
Debt Repayment i	-1.5M	-5.0M	-8.8M	-46.2M	-13.8M
Financing Cash Flow i	1.7M	6.8M	10.0M	51.7M	14.6M
Free Cash Flow i	-3.7M	-2.1M	-4.6M	-10.3M	-5.9M
Net Change in Cash i	-9.4M	-13.0M	-25.1M	21.1M	8.3M

Cash Flow Trend

Neovacs Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) 0.00

Forward P/E 9.90

Price to Book 0.01

Price to Sales 1.11

PEG Ratio 9.90

Profitability Ratios

Profit Margin 11.58%

Operating Margin -7,356.60%

Return on Equity -98.39%

Return on Assets -11.09%

Financial Health

Current Ratio 0.64

Debt to Equity 1.28

Beta -56.95

Per Share Data

EPS (TTM) €-216.07

Book Value per Share €103.50

Revenue per Share €2.49

Peer Financial Comparison

Company	Market Cap	P/E Ratio	P/B Ratio	ROE	Profit Margin	Debt/Equity
alnev	483.4K	0.00	0.01	-98.39%	11.58%	1.28
Abivax SA	4.5B	-22.33	-597.06	-196.12%	0.00%	-16.16
Valneva SE	644.5M	70.64	3.33	-44.11%	-43.21%	120.48
Ose	140.4M	4.15	2.08	86.29%	44.88%	72.30
Transgene S.A	136.7M	-	8.96	-220.48%	0.00%	68.38
Adocia S.A	126.1M	-6.69	-30.51	301.75%	-76.88%	-3.83

Financial data is updated regularly. All figures are in the company's reporting currency.